ACOG
Alpha Cognition Inc. Common StockACOG
ACOG
About: Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
Employees: 57
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1.3% more ownership
Funds ownership: 38.27% [Q4 2024] → 39.57% (+1.3%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
4% less funds holding
Funds holding: 23 [Q4 2024] → 22 (-1) [Q1 2025]
7% less capital invested
Capital invested by funds: $34.9M [Q4 2024] → $32.4M (-$2.46M) [Q1 2025]
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$20
85%
upside
Avg. target
$20
85%
upside
High target
$20
85%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju | 85%upside $20 | Buy Reiterated | 16 May 2025 |
Financial journalist opinion
Based on 5 articles about ACOG published over the past 30 days
Neutral
Business Wire
3 days ago
Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer's Association International Conference
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical data on ZUNVEYL at the Alzheimer's Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada. The Company will share the following poster presentations: Bioequivalence of ZUNVEYL,.
Positive
Zacks Investment Research
1 week ago
What Makes Alpha Cognition Inc. (ACOG) a New Strong Buy Stock
Alpha Cognition Inc. (ACOG) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
Business Wire
1 week ago
Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced preclinical data supporting the continued development of ALPHA-1062 for the treatment of mild traumatic brain injury (mTBI). The data provides additional evidence of benefits of ALPHA-1062, in the treatment of mTBI resulting from repetitive blast.
Positive
Zacks Investment Research
1 week ago
Is Alpha Cognition Inc. (ACOG) Outperforming Other Medical Stocks This Year?
Here is how Alpha Cognition Inc. (ACOG) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.
Positive
Zacks Investment Research
3 weeks ago
Should You Buy Alpha Cognition Inc. (ACOG) After Golden Cross?
Alpha Cognition Inc. (ACOG) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ACOG's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Neutral
Seeking Alpha
1 month ago
Alpha Cognition: Launching A Differentiated Drug Into A Large Alzheimer's Market Opportunity
Zunveyl nearly eliminates the onerous GI and sleep disturbance side effects of gold-standard AChEI drugs used to treat Alzheimer's. With failure of anti-amyloid antibodies and no clear disease-modifying therapies in late-stage development (yet), the $5.5 billion Alzheimer's market is severely underserved and dissatisfied. Lean, experienced commercial team launched Zunveyl in March into the long-term care (LTC) market vertical, which accounts for 32% of Alzheimer's scripts.
Neutral
Newsfile Corp
1 month ago
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025
Dallas, Texas--(Newsfile Corp. - May 19, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition began 2025 by launching ZUNVEYL(R) (benzgalantamine) to the U.S. long-term care (LTC) market on March 17, 2025, delivering on its commercialization timeline and budget.
Neutral
Seeking Alpha
1 month ago
Alpha Cognition Inc. (ACOG) Q1 2025 Earnings Call Transcript
Alpha Cognition Inc. (NASDAQ:ACOG ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Henry Du - Interim CFO Michael McFadden - CEO Lauren D'Angelo - COO Conference Call Participants Ram Selvaraju - H.C. Wainwright Michael Freeman - Raymond James Dave Storms - Stonegate Operator Greetings and welcome to the Alpha Cognition earnings call.
Negative
Zacks Investment Research
1 month ago
Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates
Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.75 per share a year ago.
Neutral
Business Wire
1 month ago
Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”) today announced its financial results for the first quarter ended March 31, 2025. “We closed the quarter on a strong note, launching ZUNVEYL® to the long-term care market,” said Michael McFadden, Chief Executive Officer. “We feel that the company is operating at a high level and are on schedule and within budget on all of our launch plans. Early market feedback on ZUNVEYL util.
Charts implemented using Lightweight Charts™